Layman’s Synopsis of 2D6 & lack of that pathway in some leading to disaster

[Guest guest]

National Coalition of Organized Women

From Laboring Women to Labor Unions, We Move as One

www.ProgressiveConvergence.com

From the desk of the

Director:

2011

An argument for genetic testing in mental illness as “Standard of

Care”:

Toxic Sensitivity Behavior Performance (TSBP) or the more dangerous

Iatrogenic Sociopathic Syndrome (ISS) induced by a physician, by medical

treatment or diagnostic procedures puts the public at great risk.

Homicides, school shootings, random acts of violence, mental illness and

suicides are on a meteoric rise since the introduction of anti

depressants, SSRIs and other modern psyche drugs.

An “inadvertent” induction of TSBP or ISS by a psychiatrist can no longer

serve as a credible or legal excuse for iatrogenic harm to the patient

and safety risk to the public at large considering the wealth of

research, science-based evidence and clinical reports since the mapping

of genes and the identification of GENETIC POLYMORPHISMS OF CYTOCHROME

P450 (CYP) 2D6 and other alleles since the 1980s.

An efficient 2D6 metabolic pathway is required in order to metabolize

more than 25% of all psyche drugs. Polymorphism of cytochrome P450 is

significant in the population. As much as 7-10% of Caucasians, for

example, are poor metabolizers or absent 2D6; 20% of Tanzanian

Africans. A limited demographic chart can be found at

http://www.pharmacologyweekly.com/table-cyp2d6-genetic-polymorphisms-pharmacogenetics

.. A list of the drugs that need the 2D6 and other alleles can be

found

http://vaccineliberationarmy.com/wp-content/uploads/2011/08/CYP-450-table-PDF.pdf

More frequently pharmaceutical manufacturers are being sued, settling

cases and paying out millions of dollars for Failure To

Warn. For example, it was successfully argued that the Eli

Lilly Company failed to publicize research showing some people are “poor

metabolizers of Prozac” while a test can reveal if a patient might be

affected.

Cassidy vs. Eli Lilly, 2002

Soon Hospitals and Psychiatrists will join the ranks of failed

defendants, as medical malpractice attorneys become educated in the

subject of gene testing and psychiatry, thereby opening up channels for

multiple level litigations. Due to the ever expanding field

of pharmacogenetics, and the ever increasing inclusion of information on

Cytochrome P450 in manufacturers’ package inserts, (specifically

information on 2D6) there is no question that psychiatric directors of

hospitals, mental health clinics directors and psychiatrists in general

have working knowledge and have, indeed, had sufficient knowledge of

genetic polymorphism of Cytochrome P450 2D6 and other alleles for the

past 10-15 years. Clearly disregarding this knowledge,

psychiatrists have “failed to warn” their patients putting them in harms

way and the public at great risk.

Regards,

Eileen Dannemann

ncowmail@...